GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Xvivo Perfusion AB (OTCPK:XVIPF) » Definitions » GF Value

XVIPF (Xvivo Perfusion AB) GF Value : $43.22 (As of Mar. 28, 2025)


View and export this data going back to 2014. Start your Free Trial

What is Xvivo Perfusion AB GF Value?

As of today (2025-03-28), Xvivo Perfusion AB's share price is $30.285. Xvivo Perfusion AB's GF Value is $43.22. Therefore, Xvivo Perfusion AB's Price-to-GF-Value for today is 0.70. Based on the relationship between the current stock price and the GF Value, GuruFocus believes Xvivo Perfusion AB is Significantly Undervalued.

The GF Value represents the intrinsic value of a stock, determined using GuruFocus' proprietary methodology. The GF Value Line on our stock Summary page provides an estimate of the stock’s fair-trading value.

To calculate this value, GuruFocus follows these steps:

  1. We analyze historical correlations between the stock price and key business performance metrics, such as revenue, earnings, cash flow, and book value.
  2. We identify the metrics that have the strongest historical correlation with the stock price and determine the historical multiples at which the stock has traded relative to these metrics.
  3. Using these historical multiples as a reference, we estimate the stock's fair value while accounting for future business growth. Adjustments may be made based on the company’s past returns and growth trends.

GuruFocus believes that the GF Value Line represents the fair value at which a stock should trade. Stock prices typically fluctuate around this line. If a stock’s price is significantly above the GF Value Line, it is considered overvalued, and its future returns are likely to be lower. Conversely, if the stock price is significantly below the GF Value Line, its future returns are likely to be higher.

Please note that "Possible Value Trap, Think Twice" applies to companies that appear significantly undervalued but are either experiencing a long-term business decline or facing financial distress.


Xvivo Perfusion AB  (OTCPK:XVIPF) GF Value Explanation

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 ratings:

Posssible Evaluations All-in-One Screener Examples (2)
Possible Value Trap, Think Twice (1)Predictable Companies that possibly be Value Traps
Significantly OvervaluedPredictable Companies which are Significantly Overvalued
Modestly OvervaluedPredictable Companies which are Modestly Overvalued
Fairly ValuedPredictable High Quality Companies which are Fairly Valued
Modestly Undervalued (3)Predictable High Quality Companies which are Modestly Undervalued
Significantly Undervalued (3)Predictable High Quality Companies which are Significantly Undervalued

(1) "Possible Value Trap, Think Twice" applies to companies that appear significantly undervalued but are either experiencing a long-term business decline or facing financial distress.

(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.

(3) A sufficient margin of safety exists only when the stock is undervalued.

Xvivo Perfusion AB's Price-to-GF-Value for today is calculated as

Price-to-GF-Value=Share Price/GF Value
=30.285/43.22
=0.70

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Xvivo Perfusion AB GF Value Related Terms

Thank you for viewing the detailed overview of Xvivo Perfusion AB's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Xvivo Perfusion AB Business Description

Traded in Other Exchanges
Address
Gemenskapens gata 9, Molndal, SWE, SE-431 53
Xvivo Perfusion AB is a medical technology company dedicated to extending the life of all major organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments namely, Thoracic: Sales of lung and heart transplant products, Abdominal: Sales of liver and kidney transplant products. Services: Revenue from sales of services in organ recovery (carried out by subsidiary STAR Teams Inc.). The majority of revenue is derived from the Thoracic segment. Geographically, the majority is from the United States.